Pacylex Pharmaceuticals Revenue and Competitors

Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. PCLX-001 is a small molecule, N-myristoylation inhibitor that selectively kills cultured human leukemia and lymphoma cells ex-vivo, completely shrinks leukemia and lymphoma tumors in mice including tumors from drug resistant patients, and strongly inhibits growth of solid tumors in mice including breast and certain lung cancers. In an ongoing Phase 1 clinical trial, PCLX-001 has excellent bioavailability, half-life, and drug exposure with an acceptable safety profile to date when administered orally once daily to patients with relapsed advanced solid tumors or refractory B-cell lymphomas. Since this Phase 1 dose escalation clinical study is nearing the target recommended Phase 2 dose (RP2D), Pacylex is planning to expand the clinical program to AML at MD Anderson this fall in a DoD-supported Phase 2 study, as well as start two Phase 2 studies in DLBCL and solid tumor patients.